Detection of abnormal glucose tolerance in Africans is improved by combining A1C with fasting glucose: the Africans in America Study

Anne E Sumner, Caroline K Thoreson, Michelle Y O'Connor, Madia Ricks, Stephanie T Chung, Marshall K Tulloch-Reid, Jay N Lozier, David B Sacks, Anne E Sumner, Caroline K Thoreson, Michelle Y O'Connor, Madia Ricks, Stephanie T Chung, Marshall K Tulloch-Reid, Jay N Lozier, David B Sacks

Abstract

Objective: Abnormal glucose tolerance is rising in sub-Saharan Africa. Hemoglobin A1c by itself and in combination with fasting plasma glucose (FPG) is used to diagnose abnormal glucose tolerance. The diagnostic ability of A1C in Africans with heterozygous variant hemoglobin, such as sickle cell trait or hemoglobin C trait, has not been rigorously evaluated. In U.S.-based Africans, we determined by hemoglobin status the sensitivities of 1) FPG ≥5.6 mmol/L, 2) A1C ≥ 5.7% (39 mmol/mol), and 3) FPG combined with A1C (FPG ≥5.6 mmol/L and/or A1C ≥5.7% [39 mmol/mol]) for the detection of abnormal glucose tolerance.

Research design and methods: An oral glucose tolerance test (OGTT) was performed in 216 African immigrants (68% male, age 37 ± 10 years [mean ± SD], range 20-64 years). Abnormal glucose tolerance was defined as 2-h glucose ≥7.8 mmol/L.

Results: Variant hemoglobin was identified in 21% (46 of 216). Abnormal glucose tolerance occurred in 33% (72 of 216). When determining abnormal glucose tolerance from the OGTT (2-h glucose ≥7.8 mmol/L), sensitivities of FPG for the total, normal, and variant hemoglobin groups were 32%, 32%, and 33%, respectively. Sensitivities for A1C were 53%, 54%, and 47%. For FPG and A1C combined, sensitivities were 64%, 63%, and 67%. Sensitivities for FPG and A1C and the combination did not vary by hemoglobin status (all P > 0.6). For the entire cohort, sensitivity was higher for A1C than FPG and for both tests combined than for either test alone (all P values ≤ 0.01).

Conclusions: No significant difference in sensitivity of A1C by variant hemoglobin status was detected. For the diagnosis of abnormal glucose tolerance in Africans, the sensitivity of A1C combined with FPG is significantly superior to either test alone.

Trial registration: ClinicalTrials.gov NCT00484861.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Figures

Figure 1
Figure 1
Bland-Altman plot for agreement between A1C determined by boronate affinity method and HPLC. The x-axis presents the mean of the two determinations and the y-axis the difference. The ■ represent the 68 participants with normal hemoglobin. The □ represent the 22 participants with variant hemoglobin.

References

    1. International Diabetes Federation IDF Diabetes Atlas. 6th ed. Brussels, International Diabetes Federation, 2013
    1. Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes Care 2010;33(Suppl. 1):S3.
    1. Di Pino A, Scicali R, Calanna S, et al. . Cardiovascular risk profile in subjects with prediabetes and new-onset type 2 diabetes identified by HbA(1c) according to American Diabetes Association criteria. Diabetes Care 2014;37:1447–1453
    1. Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010;33:2104–2109
    1. Piel FB, Howes RE, Patil AP, et al. . The distribution of haemoglobin C and its prevalence in newborns in Africa. Sci Rep 2013;3:1671.
    1. Piel FB, Patil AP, Howes RE, et al. . Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013;381:142–151
    1. Allison AC. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Trans R Soc Trop Med Hyg 1954;48:312–318
    1. Hanchard NA, Hambleton I, Harding RM, McKenzie CA. The frequency of the sickle allele in Jamaica has not declined over the last 22 years. Br J Haematol 2005;130:939–942
    1. Meyer LM, Adams JG 3rd, Steinberg MH, Miller IE, Stokes N. Screening for sickle cell trait: the Veterans Administration National Sickle Cell Program. Am J Hematol 1987;24:429–432
    1. Taylor C, Kavanagh P, Zuckerman B. Sickle cell trait—neglected opportunities in the era of genomic medicine. JAMA 2014;311:1495–1496
    1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
    1. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518–523
    1. Little RR, Rohlfing CL, Sacks DB National Glycohemoglobin Standardization Program (NGSP) Steering Committee . Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57:205–214
    1. Bianchi C, Miccoli R, Bonadonna RC, et al. GENFIEV Investigators . Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care 2012;35:2607–2612
    1. Cowie CC, Rust KF, Byrd-Holt DD, et al. . Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010;33:562–568
    1. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010;33:2184–2189
    1. O’Connor MY, Thoreson CK, Ricks M, et al. . Worse cardiometabolic health in African immigrant men than African American men: reconsideration of the healthy immigrant effect. Metab Syndr Relat Disord 2014;12:347–353
    1. Ukegbu UJ, Castillo DC, Knight MG, et al. . Metabolic syndrome does not detect metabolic risk in African men living in the U.S. Diabetes Care 2011;34:2297–2299
    1. Yu SS, Ramsey NL, Castillo DC, Ricks M, Sumner AE. Triglyceride-based screening tests fail to recognize cardiometabolic disease in African immigrant and African-American men. Metab Syndr Relat Disord 2013;11:15–20
    1. American Diabetes Association . Executive summary: Standards of medical care in diabetes—2014. Diabetes Care 2014;37(Suppl. 1):S5–S13
    1. Sumner AE, Luercio MF, Frempong BA, et al. . Validity of the reduced-sample insulin modified frequently-sampled intravenous glucose tolerance test using the nonlinear regression approach. Metabolism 2009;58:220–225
    1. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 2003;5:1003–1015
    1. NGSP. HbA1c assay interferences. Available from . Accessed 8 May 2014
    1. Cowie CC, Rust KF, Byrd-Holt DD, et al. . Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263–1268
    1. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49:791–801
    1. McCurdy PR. 32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes. Blood 1969;33:214–224
    1. Prindle KH Jr, McCurdy PR. Red cell lifespan in hemoglobin C disorders (with special reference to hemoglobin C trait). Blood 1970;36:14–19
    1. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;47:153–163
    1. Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009;16:113–118
    1. John W, Little RR, Sacks DB, et al. . Multicentre evaluation of the Premier Hb9210 HbA1c analyser. Clin Chem Lab Med 2 Oct 2014. [Epub ahead of print]
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Li G, Zhang P, Wang J, et al. . Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014;2:474–480
    1. Lindström J, Ilanne-Parikka P, Peltonen M, et al. Finnish Diabetes Prevention Study Group . Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673–1679
    1. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893–2898

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅